Join Growin Stock Community!

原創生醫6483.TW Overview

TW StockBiotech. & Medical
(No presentation for 6483)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

原創生醫（6483）Overall Performance

原創生醫（6483）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

原創生醫（6483） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

原創生醫（6483）Key Information

原創生醫（6483）Profile

Original BioMedicals Co., Ltd., a biotechnology company, chemical entities to solve unmet medical needs in Taiwan. It develops (A01) Radprotect, a pre-clinical product to protects against radiation exposer; (A02) CCM-Ami, which protects normal tissues from the toxic effects of chemotherapeutic agents and ionizing radiation; and ((P01)GLP-1 CCM for the treatment of type 2 diabetes. The company was founded in 2011 and is based in Taipei, Taiwan.

原創生醫（6483）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2566.41
PB Ratio
5.17
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
80.42%
Net Margin
-33386.56%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.13
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2566.41
PB Ratio
5.17
Price-to-FCF
-
Gross Margin
80.42%
Net Margin
-33386.56%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6483

原創生醫

16.40D

-9.15%

(-0.09)

  • When is 6483's latest earnings report released?

    The most recent financial report for 原創生醫 (6483) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6483's short-term business performance and financial health. For the latest updates on 6483's earnings releases, visit this page regularly.

  • What is the operating profit of 6483?

    According to the latest financial report, 原創生醫 (6483) reported an Operating Profit of -49.54M with an Operating Margin of -13,003.67% this period, representing a decline of 37.97% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6483's revenue growth?

    In the latest financial report, 原創生醫 (6483) announced revenue of 381K, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6483 have?

    At the end of the period, 原創生醫 (6483) held Total Cash and Cash Equivalents of 107.9M, accounting for 0.46 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6483 go with three margins increasing?

    In the latest report, 原創生醫 (6483) did not achieve the “three margins increasing” benchmark, with a gross margin of 80.31%%, operating margin of -13,003.67%%, and net margin of -12,492.91%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6483's profit trajectory and future growth potential.

  • Is 6483's EPS continuing to grow?

    According to the past four quarterly reports, 原創生醫 (6483)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.72. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6483?

    原創生醫 (6483)'s Free Cash Flow (FCF) for the period is -2K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 99.8% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.